BioCardia Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
BCDA$0.90+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
BIOCARDIA, INC.
Consolidated Statements of Operations
(In thousands, except share and per share amounts)
| Years ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue: | ||
| Net product revenue | $— | $3 |
| Collaboration agreement revenue | 477 | 1,349 |
| Total revenue | 477 | 1,352 |
| Costs and expenses: | ||
| Research and development | 7,726 | 8,834 |
| Selling, general and administrative | 4,395 | 4,419 |
| Total costs and expenses | 12,121 | 13,253 |
| Operating loss | (11,644) | (11,901) |
| Other income (expense): | ||
| Total other income (expense), net | 73 | (6) |
| Net loss | $(11,571) | $(11,907) |
| Net loss per share, basic and diluted | $(0.55) | $(0.67) |
| Weighted-average shares used in computing net loss per share, basic and diluted | 21,179,974 | 17,720,972 |
See accompanying notes to consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.